Form 8-K - Current report:
SEC Accession No. 0001193125-22-144265
Filing Date
2022-05-09
Accepted
2022-05-09 07:05:57
Documents
14
Period of Report
2022-05-09
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d334684d8k.htm   iXBRL 8-K 36935
2 EX-99.1 d334684dex991.htm EX-99.1 37979
6 GRAPHIC g334684g0509022325762.jpg GRAPHIC 2867
  Complete submission text file 0001193125-22-144265.txt   213807

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA axsm-20220509.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE axsm-20220509_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE axsm-20220509_pre.xml EX-101.PRE 11251
8 EXTRACTED XBRL INSTANCE DOCUMENT d334684d8k_htm.xml XML 3356
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 22903212
SIC: 2834 Pharmaceutical Preparations